NCT05953168尚未招募2 期
An Open-label, Single-arm Phase II Trial of First-line Treatment With Trastuzumab Deruxtecan for Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer, Luminal Androgen Receptor Subtype With Low Human Epidermal Growth Factor Receptor 2 (HER2) Expression.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 69
- 试验地点
- 1
- 主要终点
- Objective Response of Complete Response (ORR)
研究概览
简要总结
This is an open-label, single-arm phase II trial of first-line treatment with trastuzumab deruxtecan (T-DXd) for patients with locally advanced or metastatic triple-negative breast cancer, luminal androgen receptor subtype (TNBC-LAR) with low HER2 expression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women aged 18-70 years old;
- •Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score 0 or 1;
- •Expected lifetime of not less than three months;
- •Disease-free interval >6 months；
- •Adequate tumor tissue samples collected within a time frame of less than 3 months;
- •Histological results recorded as TNBC [negative HER2, ER, and progesterone receptor (PgR) status] and LAR subtype according to the classification of Fudan University Shanghai Cancer Center (FUSCC);
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1);
- •Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resected;
- •Adequate hematologic and end-organ function, laboratory test results;
- •Within the 3 weeks prior to study initiation, patients have not received radiotherapy, endocrine therapy, targeted therapy, or surgery, and have recovered from acute toxicities associated with previous treatments (if surgery was performed, wound healing is complete); no peripheral neuropathy or grade I peripheral neurotoxicity.
- •Female subjects with fertility are required to use a medically approved contraceptive method during the study treatment；
- •Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.
排除标准
- •Use of radiotherapy (except for palliative reasons), chemotherapy, and immunotherapy in the 3 weeks prior to treatment, excluding bisphosphonates (which can be used for bone metastasis)；
- •History of clinically uncontrolled heart disease, including congestive heart failure, angina, myocardial infarction within the past 6 months, or ventricular arrhythmias；
- •Common Terminology Criteria for Adverse Events (CTCAE) grade ≥1 adverse reactions attributed to previous treatments；
- •Underwent major surgery (excluding outpatient minor procedures, such as placement of vascular access) within the first 3 weeks of the investigational treatment；
- •Pregnant or lactating patients；
- •History of malignancy within the past five years (excluding cured basal cell carcinoma and cervical carcinoma in situ)；
- •Presence of third-space fluid accumulation (such as significant pleural effusion and ascites) that cannot be controlled by drainage or other methods；
- •Non-infectious interstitial lung disease (ILD) or non-infectious pneumonia requiring steroid hormone therapy, current ILD/non-infectious pneumonia, or suspected ILD/non-infectious pneumonia that cannot be ruled out by imaging examinations during screening (Note: Subjects found to have ILD/non-infectious pneumonia during baseline screening chest CT are ineligible)；
- •Known active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection or HBV DNA ≥500, or patients with chronic phase accompanied by abnormal liver function；
- •Individuals with allergies or a history of known allergy to components of the study drugs or other monoclonal antibodies；
- •History of immunodeficiency, including HIV-positive test results, acquired or congenital immunodeficiency diseases, or history of organ transplantation. Positive syphilis antibody test；
- •According to the investigator's judgment, any evidence of diseases that the investigator considers unfavorable for the subject's participation in the study or that may affect their adherence to the protocol.
研究组 & 干预措施
Trastuzumab Deruxtecan (T-DXd)
Experimental
干预措施: Trastuzumab Deruxtecan (Drug)
结局指标
主要结局
Objective Response of Complete Response (ORR)
时间窗: 3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first)
Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 in all Participants
次要结局
- Duration of response (DOR)(3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first))
- Overall Survival (OS)(Every 6 months)
- Disease Control Rate (DCR)(3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first))
- Progression Free Survival (PFS)(3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Trial of Trastuzumab Deruxtecan in Previously Treated HER2Breast Cancer MetastaticNCT06750484Yale University40
招募中
2 期
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerEarly-stage Breast CancerHormone Receptor Positive Breast CarcinomaStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerInvasive Breast CancerNCT04553770Jonsson Comprehensive Cancer Center88
招募中
2 期
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial CarcinomaCarcinoma, Transitional CellHER-2 Gene AmplificationNCT05318339Chinese Academy of Medical Sciences30
招募中
1 期
Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse. TRANSCENDER Study”MedDRA version: 23.0Level: PTClassification code: 10065430Term: HER2 positive breast cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104Metastatic breast cancerCTIS2023-503627-26-00Grupo Espanol De Investigacion En Cancer De Mama41
已完成
2 期
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerMetastatic Breast CancerNCT00509769Genentech, Inc.112